• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to peptides, in particular, their preparation in the form of acid addition salts of the general formula I X-Arg-Lys-Y, where X is H, Ser; Y - Asp, Asp-Val, Asp-Val-NH, Asp-Val-OCHg, Asn-Val, Asp-Ala, Asp-lie, Ala-Val, Glu-Val, Asu-Val, which have immunological activity - and can be used in biology and medicine. To reveal the activity among the peptides, new ones were obtained. Their synthesis is carried out by stepwise growth of the peptide chain, starting from C-terminal amino acid ester, by the method of activated esters and by the method of mixed anhydrides with subsequent cleavage of protective g groups from the final protected peptide by catalytic hydrogenolysis. Tests 1 show that they have a wider spectrum of immunos of regulatory action with low toxicity than known peptides. 6 tab. to-h; about about with
    公开号:SU1277903A3
    申请号:SU823454444
    申请日:1982-06-11
    公开日:1986-12-15
    发明作者:Кишфалуди Лайош；Ньеки Олга；Шен Иштван；Денеш Ласло；Эмбер Юлиа；Хайош Дьердь；Спорни Ласло；Сенде Бела
    申请人:Рихтер Гедеон Ведьесети Дьяр Рт (Инопредприятие)；
    IPC主号:
    专利说明:

    This invention relates to a process for the production of new peptides.
    X-Arg-Lys-V
    acid addition salts, de X - hydrogen, Glp;
    V-Asp, Asp-Val, Asp-Val-NII ,,, Asp-al-OMe, Asn-Val, Asp-Ala, Asp-lie, la-Val, Gly-Val, Asu-Val, have their immunomodulatory activity, which can be used in experimental biology and medicine. The purpose of the invention is a method for producing new peptides with a wider spectrum of immunoregulatory effects.
    Abbreviations: Z, benzyl-oxycarbonyl-; Voye - tert-butyloxy-carbonyl-; tert-butyloxy; Opfp - pentafluorophenoxy; Asu - aminosuccinyl-; OMe is methoxy; OBzl - benzyloxy-; ONE - 4-: shtrobenziloksi-group; DMF - dimethylformamide; TEA - triethylamine.
    The melting point is determined using a Tottoli device from Biši (Switzerland). The homogeneity of the intermediate and end compounds is monitored using thin-layer chromatography on Merck silica gel plates (FRG) in the following systems:
    1- etchtacetate- (pyridine-acetic acid-water, 20: 6: 11), 95: 5;
    2-ethnyl acetate - (pyrindine-acetic acid-water, 20: 6: 11), 9: 1;
    3- ethtacetate - (pyridine-acetic acid - water, 20.5: 11), 4: 1;
    4-ethyl acetate - (pyridine-acetic acid - water, 20: 6: 11), 3: 2;
    5-n-butanol - (pyridine-acetic acid - water, 20: 6: 11) ,, 3: 7;
    6- chloroform - methanol, 9: 1;
    7-n-butanol - acetic acid - water, 1: 1: 1;
    8-n-butanol - acetic acid - water, 4: 1: 5.
    . Chromatograms were shown with ninhydrin after chlorination with K-tolidine. Optical density was measured on a Perkin-Elmer 141 digital photoelectric field (United States). The solvents were distilled off on a rotary evaporator of the firm (Switzerland) in a water bath with a temperature not higher.
    Example 1 (Method A). Z-Arg (N02) -Lys (Z) -Asp (OBzl) -Val-ONB (1). To a solution of 1.73 g (6.0 mmol) Val79032
    ONB HCl in 15 m, h of DMF was added 0.84 ml (6.0 mmol) of triethyl amine and 2.45 g (5.0 mmol) of Boc-Asp-OPfp.
    The reaction mixture is stirred for 5 to 30 minutes at room temperature, evaporated, the residue is dissolved in 30 ml of ethyl acetate. The rastirr washed with 15 ml and. hydrochloric acid, 15 ml of 5% sodium bicarbonate solution and 15 ml
    fO
    15
    water, dried over anhydrous sodium sulphate and evaporated in vacuo. The resulting protected dipeptide (, 0.9) is dissolved in 10 ml of 8 and. HC in dioxane, 40 ml added after 15 minutes
    35
    anhydrous ether and evaporated to dryness. The free dipeptide obtained as a residue (R g 0.5) was dissolved in 10 ml of DMF, the pH of the solution was adjusted with triethylamine to 8.0 and 3.1 g (5.5 mmol) of Boc-Lys- / Z was added. / - OPfp. The reaction mixture is stirred for 30 minutes, maintaining the pH at 8.0 with triethylamine, diluted
    2 60 ml of chloroform and washed with 15 ml of 1N. hydrochloric acid and 15 ml of water., dried with anhydrous sodium sulfate and evaporated, the residue evaporated with anhydrous ether. The resulting protected 30 tripeptide (Rj 0.4) is planted with
    100 ml of anhydrous ether, filtered, washed twice with ether and dissolved in 20 ml of DMF. Triethylamine was added to the resulting solution to a pH of 8.0 and then 3.3 g (7.0 mmol) ./N02/OPfp. The reaction mixture is stirred for 30 minutes, the pH is maintained at 8.0 with triethylamine, evaporated, the residue is triturated with 50 ml of ethano Q la, filtered off 5 and washed with ethanol (2 to 10 ml). In the end, get 3.85 g (, 73%) 1 with so pl. 135-148 ° C; RjO, 80.
    Example 2 (. Method B). Z-Arg
    5 (N02) -Lys (, Z) -Asp (OBzI) -OBzI (II).
    A mixture of 15.62 g (3.3 mmol) of Boc-Lys, Z) -OPfp, 1.40 g (4.0 mmol) Asp i; OBzI) -OBzI. HCl and 0.98 ml (7.0 mmol) of triethylamine in 1C ml of ethyl acetate wasp; stand for one hour at room temperature and then diluted with 20 ml of ethyl acetate. The mixture is shaken first with 10 ml of 1N hydrochloric acid solution, then with
    Her 10 ML 5% sodium bicarbonate solution, dried over anhydrous sodium sulfate and then evaporated in vacuo. The residue is solidified with n-hexane, filtered and washed with n-hexane. The resulting protected dipeptide (yield: 81.2%; mp. 92-95 ° C; R. 0.75) is treated with 30 ml of 4N hydroxyl dioxia for 30 minutes, then evaporated to a dry residue. The free dipeptide (Rj. 0.10) is dissolved in 10 ml of dimethylformamide, the solution is neutralized with 0.35 ml of triethylamine, and the resulting suspension is added to the mixed anhydride prepared as follows: 10.6 i (3.0 mmol) Z Arg (NO ,,) -OH and 0.42 ml (3.0 mmol) of triethylamine are dissolved in 5 ml of dimethylformamide. The solution is cooled to -10 s and mixed at this temperature with 0.36 ml (3.0 mmol) of pivaloyl chloride in the dropwise manner. To the solution of the mixed anhydride thus obtained, after 5 min at -10 ° C, a solution of the free peptide is added. The reaction mixture was stirred for an additional 30 minutes at OC, then left to stand overnight, and the next day evaporated to a dry residue. The residue was dissolved in 50 ml of chloroform and the solution was shaken with 10 ml of 1N. solution of hydrochloric acid, then with 10 ml of 5% sodium bicarbonate solution and, finally, with 10 ml of water. After drying, the organic phase is evaporated to a dry residue and the resulting residue is strengthened with a 1: 1 mixture of ether and n-hexane prepared. Obtain 1.82 g (yield 84%) of the protected Tripeptide with R 0,70.
    Example 3 (method C). Z-Arg (N02) -Lys (Z) -Asu Val-OH (III).
    2.51 g (12 mmol) of Val-OtBu HCl is dissolved in 50 ml of chloroform. The solution is mixed with 3.86 g (10 mmol) of Boc-Asp (OtBu) -OSu and 1.68 ml (12 mmol of triethylamine. Next day, the solution is shaken first with 3 × 10 ml of 1N hydrochloric acid, then with ml of 5% sodium bicarbonate solution. After drying, the solvent is distilled off. The protected dipeptide obtained as a residue (R g, 0.80) is dissolved in 30 ml of 5 N acetic acid containing hydrogen bromide and the solution is left to stand for week. Then the reaction mixture is evaporated to dryness and the residue is solidified with anhydrous ether. 2.65 g (98.2%) Asu-Val-OH is obtained
    Hbr (R 0.15) and acylated further by the method described in Example 1. The data of the protected tetrapeptide is contained in Table. five.
    Example 4. Arg-Lys-Asp-Val. AcOH (IV).
    5 2.25 g (2.22 mmol) Z-Arg (NOp-Lys (Z) -Asp (OBzI) -VaI-ONB (Example 1) is suspended in 50 ml of 90% acetic acid. The suspension is mixed with 1 g 5% of palladium on active carbon and hydrogen are passed through the mixture for 14 h. Then the catalyst is filtered off, washed with 2 "10 ml of 90% acetic acid, the filtrate is combined with industrial liquid and then evaporated to a dry residue. The residue with water and ethanol again evaporated, then dissolved in 2 ml of water and mixed with 30 ml of ethanol. The resulting suspension is filtered and oca
    15
    20
    25
    thirty
    dock is rinsed with ethanol. Obtain 0.92 g (80%) IV. -24.8 ° (C1; 10% AcOH); R | Oh, 10.
    Amino acid analysis: Lys 1.05 Cl; Arg 0.95 (1); Asp 1.04 (1); Val
    0.93 (1).
    Example 5. Gip-Arg-Lys-Asp-Val AcOH (V).
    4.1 g of IBoc-Lys (Z) -Asp (OBzI) -Val-ONB are dissolved in 10 ml of 8N. HC1 hydrochloric acid in dioxane, after 15 minutes, 100 ml of anhydrous ether are added, the precipitated precipitate is filtered off, washed twice with ether and dissolved in 20 ml of DMF. To the resulting 35 solution, triethylamine was added to pH 8.0, and then 3.5 g of Boc-Arg (NO,) - POfp and 0.98 ml of triethylamine. The reaction mixture is stirred for 1 h, evaporated, the residue is triturated with
    0
    50 ml of ethanol, filtered, washed with ethanol (ml). The resulting protected tetrapeptide (R g
     0.80) is dissolved in 25 ml of 8N. HC1
    in dioxane, after 15 minutes, 70 ml of anhydrous ether is added to the solution, the precipitated precipitate is filtered off, washed twice with ether and dissolved in 30 ml of DMF. Triethylamine was added to the solution to a pH of 8.0 and then 2.4 g of Glp-OPfp. The reaction mixture is stirred for 1 h, 100 ml of ethanol are added, the precipitated product is filtered off, rinsed with ethanol (2 "20 ml). In the end, get 3.9 g of Z-Glp-Arg (NOr,) - Lys (Z) -Asp (OBzl) -Val-ONB with so pl. 166-172 C, R 0,80.
    2.2 g of Z-Glp-Arg (NO) -Lys (Z) -Asp) -Val-ONB are suspended in 50 ml
    512
    90% -HCl acetic KVicjioTbi, add 1 g of 5% Pd / C and hydrogenate for 4 hours. Then the catalyst is filtered off, washed with 10 ml of 90% acetic acid, the combined filtrate is evaporated, the residue is triturated with 30 ML of ethanol, the precipitate formed is filtered off, sifted with ethanol (2 X 10 ml) and dried.
    . As a result, 1.12 g (93%) of V is obtained. The resulting product is purified by column chromatography on SI-100 silica gel using the following system: methanol - water 1: 1 as eluent. As a result, 0.74 g of V -51.3 ° (with 0.9; 10% acetic acid) is obtained.
    Similarly, a number of other peptides are obtained, the physicochemical characteristics of which are listed in Table. 1-2.
    Immunomodulatory activity of the described compounds was studied in vitro and in vivo using known methods. I. in vitro.
    The study on active E-sockets was carried out using a modified method of Wybran et al. With lymphocytes of partially healthy, partially austoimmuno-sick people (rheumatoid arthritis and systemic lupus is red). To 50 ml of cell suspension of lymphocytes, review by circumstances, add 100 ml of the test substance diluted to a concentration of from 10 to 10 mol / l. The mixture was incubated at 37 ° C in air. Containing 5% CO j for 60 min and then mixed with 50 ml of 1% suspension of erythrocytes (sheep). Then for 10 min, centrifuged with a speed of 1000 min. After that, the glass pieces were put on a modified shaking machine to combat gallstone disease and shaken for 30 s (shaking frequency: 65 min, lifting height 8 cm). In order to fix the sockets to each tube, 50 ml of 0.1% glutaraldehyde was added. After 3 minutes, under a microscope, there were more than three lymphocytes, bridging erythrocyte cells derived from sheep, and a total of cells were evaluated. Separated lymphocytes and; ity contained macrophages and polymorphic proteins as zagres.

    five
    0
    five
    0
    0
    cells 1, max., but 10%). Often, puvieTKH binding cells were corrected in each case to this value. The results are presented in Table. 3-4.
    Inhibition test with azathioprine {- sockets.
    Cell suspension containing 2 to 10 lymphocytons / ml is obtained from the blood of healthy donors, chosen randomly. The inhibition test with azathioprine E-rosettes is performed by cor jiacbio to the previously described method. Briefly, this method consists of administering 500 μl of azathioprine and 200 μl of HBSS without additives, or containing the test substance, into 200 μl of the cell suspension. The substances are tested at concentrations ranging from 1 ° C to 10 mol / L. As a comparative experiment, 200 μl of the cell suspension and 400 μl of HBSS are mixed.
    The resulting mixtures are incubated in air containing 5% carbon dioxide at 37 ° C for 1 h, then mixed with 200 μl of a suspension of 1% SRBC and centrifuge 11) at a temperature of 90 g for 5 min. 400 µl of the upper fraction (liquid) is removed and, after careful resuspension, at least 400 cells are taken to calculate the E outlets (formation of the outlet — when 3 or more SRBC
    5 surround one lymphocyte). Statistical analysis is performed using calling for student distribution.
    Due to different activity in relation to formations of E-rosettes in lymphocytes, obtained from various donors and their different inducibility by azatnoprin, substances are characterized by their ability to restore the activity of lymphocytes to the formation of E-rosettes, ing ibeiruated by azatimony, expressed as% recovery (R %):
     .O i5Kc; 2l MClA-ERFC)
    ERFC - Az-ERFC
    where ERFC and Az-ERFC represent the average percentage of cells that form E-rosettes, without inhibitor and in the presence of azathioprine, respectively.
    Exp-ERFC is a pro UefJT of cells forming E-rosettes in the presence of azathioprine and experimentally I o substance.
    0
    55
    The resulting re: ultates 111 are shown in Table. five.
    Ii. in vivo.
    one . To study the effect of antibody production, the Tsetlovsky method was chosen.
    Winter to rats at the latest at the 12th hour after their birth was intraperitoneally injected with the substance to be studied in the form of 25 ml of liquid with a concentration from 4-1U to 410 mol / l (a single dose for every 9 animals). At the age of 14 days, animals were immunized by intraperitoneal administration to each 0.5 ml of 5% sheep erythrocyte suspension, and on the 7th day after immunization, the animals were exsanguinated by decapitation. The blood of every three animals is pooled, centrifuged for 3 minutes at a speed of 3000 minutes, and the antibody titer is determined by the method Tak tsy in the thus obtained short.
    The results were expressed as an agglutination titer, with the highest dilution of serum being taken as the titer, at which agglutination is still distinguishable. The results are summarized in table. 6
    2. The number of cells producing specific antimatter was determined by the Ganningham method.
    The essence of the method is that a homogeneous suspension is prepared from the cells of the spleen of immunized animals, from a suspension of sheep erythrocytes and complement, and is introduced into the chamber suitable for the development of single-cell layers. Around the cells producing antimatter, a gradual halo is formed and the number of these halos (spots) is identical with the number of cells, and their number is identical. ci;
    digital antimatter (Plagito forming cells, PFC).
    Experimental animals
    The 12th hour after their ro cdepi was once treated with the substance to be studied. According to the method of (1) each substance was studied in three doses. On the 7th day
    After immunization, the ability of the splenic cells steamed from animals to form Plague was studied.
    In tab. 7 shows the quotient of the number of Plagues la treated animals and the number of Plagues untreated control animals. I
    As can be seen from the data given in table. 3-7, the compounds obtained by the proposed method have a broad spectrum of immunomodulatory effects in combination with low toxicity.
    权利要求:
    Claims (2)
    [1]
     The invention relates to a process for the preparation of new peptides of the general formula X-Arg-Lys-V in the form of acid addition salts, where X is hydrogen, Glp; V-Asp, Asp-Val, Asp-Val-NII ,,, AspVal-OMe, Asn-Val, Asp-Ala, Asp-lie, Ala-Val, Gly-Val, Asu-Val, which have immunomodulatory activity that can to find application in experimental biology and medicine. The purpose of the invention is a method for producing new peptides with a wider spectrum of immunoregulatory effects. Abbreviations: Z - benzyloxycarbonyl-; Baugh - tert-butyloxycarbonyl-; tert-butyloxy; Opfp - pentafluorophenoxy; Asu - amine nosuccinyl-; OMe is methoxy; OBzl benzyloxy; ONE - 4-: schtrobenzyloxy group; DMF - dimethylformamide; TEA - triethylamine. The melting point is determined using a Tottoli device manufactured by Biichi (Switzerland). The homogeneity of the intermediate and final compounds is monitored using thin-layer chromatography on plates with Merck silica gel (Germany) in the following systems: 1-etchtacetate- (pyridine-acetic acid-water, 20: 6: 11), 95: 5; 2-ethnyl acetate - (pyrindine-acetic acid-water, 20: 6: 11), 9: 1; 3- ethtacetate - (pyridine-acetic acid - water, 20.5: 11), 4: 1; 4-ethyl acetate - (pyridine-acetic acid - water, 20: 6: 11), 3: 2; 5-n-butanol - (pyridine-acetic acid - water, 20: 6: 11) ,, 3: 7; 6- chloroform - methanol, 9: 1; 7-n-butanol - acetic acid - water, 1: 1: 1; 8-n-butanol - acetic acid - water, 4: 1: 5. . Chromatograms were shown with ninhydrin after chlorination with K-Tolidine. Specific optical resolution was measured on a Perkin-Elmer 141 digital photoelectric polarizer (United States). The solvents were distilled off on a rotary evaporator of the firm (Switzerland) in a water bath with a temperature not higher. Example 1 (Method A). Z-Arg (N02) -Lys (Z) -Asp (OBzl) -Val-ONB (1). To a solution of 1.73 g (6.0 mmol) of Val32 ONB HC1 in 15 m, 0.84 ml (6.0 mmol) of triethyl amine and 2.45 g (5.0 mmol) of Boc-Asp- OPfp. The reaction mixture was stirred for 30 minutes at room temperature, evaporated, the residue was dissolved in 30 ml of ethyl acetate. The rastirr washed with 15 ml and. hydrochloric acid, 15 ml of 5% sodium bicarbonate solution and 15 ml of water, dried over anhydrous sodium sulfate and evaporated in vacuo. The resulting protected dipeptide (, 0.9) is dissolved in 10 ml of 8 and. HC in dioxane, after 15 minutes 40 ml of anhydrous ether are added and evaporated to dryness. The free dipeptide obtained as a residue (Rg 0.5) was dissolved in 10 ml of DMF, the pH of the solution was adjusted with triethylamine to 8.0, and 3.1 g (5.5 mmol) of Boc-Lys (Z) was added. OPf. The reaction mixture is stirred for 30 minutes, maintaining the pH at 8.0 with triethylamine, diluted with 60 ml of chloroform and washed with 15 ml of 1N. hydrochloric acid and 15 ml of water., dried with anhydrous sodium sulfate and evaporated, the residue evaporated with anhydrous ether. The resulting protected tripeptide (Rj 0.4) is precipitated with 100 ml of anhydrous ether, filtered, washed twice with ether and dissolved in 20 ml of DMF. Triethylamine was added to the resulting solution to a pH of 8.0 and then 3.3 g (7.0 mmol) ./N02/OPfp. The reaction mixture is stirred for 30 minutes, the pH is maintained at 8.0 with triethylamine, evaporated, the residue is triturated with 50 ml of ethanol, and 5 are filtered off with ethanol (2 to 10 ml). In the end, get 3.85 g (, 73%) 1 with so pl. 135-148С; RjO, 80. Example 2 (. Method B). Z-Arg (N02) -Lys (, Z) -Asp (OBzI) -OBzI (II). A mixture of 15.62 g (3.3 mmol) of Boc-Lys, Z) -OPfp, 1.40 g (4.0 mmol) Asp i; OBzI) -OBzI. HCl and 0.98 ml (7.0 mmol) of triethylamine in 1C ml of ethyl acetate are left to stand for one hour at room temperature and then diluted with 20 ml of ethyl acetate. The mixture is shaken first with 10 ml of 1N hydrochloric acid solution, then with 10 ML of 5% sodium bicarbonate solution, dried over anhydrous sodium sulfate and then evaporated in vacuo. The residue is solidified with n-hexane, filtered and washed with n-hexane. The resulting protected dipeptide (yield: 81.2%; mp. 92-95 ° C; R. 0.75) is treated with 30 ml of 4N hydroxyl dioxane for 30 minutes, then evaporated to dryness. The free dipeptide (Rj. 0.10 is dissolved in 10 ml of dimethylformamide) the solution is neutralized with 0.35 ml of triethyl mine and the resulting suspension is added to the mixed anhydride prepared as follows: 10.6 (3.0 mmol) Z-Arg (NO, ,) -OH and 0.42 ml (3.0 mmol) of triethylamine are dissolved in 5 ml of dimethylformamide. The solution is cooled to -10 s and mixed with 0.36 ml (3.0 mmol of pivaloyl chloride) at this temperature. In this way, a solution of the free peptide is added to the mixed anhydride solution after 5 minutes at -10 ° C. The reaction mixture is stirred for 30 minutes at OC, then left to stand overnight and evaporate the next day until the residue remains dry. The residue is dissolved in 50 ml of chloroform and the solution is shaken with 10 ml of 1N hydrochloric acid, then 10 ml of 5% sodium bicarbonate solution and finally with 10 ml of water. After drying, the organic phase is evaporated to a dry residue and the resulting residue is made up with a 1: 1 mixture of ether and n-hexane prepared. Obtain 1.82 g (yield 84%) of the protected Tripeptide with R 0,70. Example 3 (method C). Z-Arg (N02) -Lys (Z) -Asu Val-OH (III). 2.51 g (12 mmol) of Val-OtBuHCl is dissolved in 50 ml of chloroform. The solution is mixed with 3.86 g (10 mmol) of Boc-Asp (OtBu) -OSu and 1.68 ml (12 mmol of triethylamine. Next day, shake the solution with sip of 1 ml of 1N hydrochloric acid, then with ml of 5% sodium bicarbonate solution. After drying, the solvent is distilled off. The protected dipeptide obtained as a residue (R g, 0.80) is dissolved in 30 ml of 5 N acetic acid containing hydrogen bromide and the solution is left to stand for week. Then the reaction mixture is evaporated to dryness and the residue is solidified with anhydrous ether. 2.65 g (98.2%) Asu-Val-OH Hbr (R 0.15) are obtained and acylated Further described in Example 1. The data of the protected tetrapeptide is contained in Table 5. Example 4. Arg-Lys-Asp-Val. AcOH (IV). 2.25 g (2.22 mmol) Z-Arg (NOp Lys (Z -Asp (OBzI) -VaI-ONB (Example 1) is suspended in 50 ml of 90% acetic acid. The suspension is mixed with 1 g of 5% palladium on active carbon and hydrogen is passed through the mixture for 14 hours. The mixture is filtered, washed with 2 "10 ml of 90% acetic acid, the filtrate is combined with industrial liquid and then evaporated to dryness. The residue with water and ethanol is again evaporated, then dissolved in 2 ml of water and mixed with 30 ml of ethanol. The resulting suspension is filtered and the precipitate is rinsed with ethanol. Obtain 0.92 g (80%) IV. -24.8 ° (C1; 10% AcOH); R | O, 10. Amino acid analysis: Lys 1.05 Cl); Arg 0.95 (1); Asp 1.04 (1); Val 0.93 (1). Example 5. Gip-Arg-Lys-AspVal AcOH (V). 4.1 g of IBoc-Lys (Z) -Asp (OBzI) -ValONB are dissolved in 10 ml of 8N. HC1 hydrochloric acid in dioxane, after 15 minutes, 100 ml of anhydrous ether are added, the precipitated precipitate is filtered off, washed twice with ether and dissolved in 20 ml of DMF. Triethylamine was added to the resulting solution to pH 8.0, followed by 3.5 g of Boc-Arg (NO,) POfp and 0.98 ml of triethylamine. The reaction mixture is stirred for 1 h, evaporated, the residue is triturated with 50 ml of ethanol, filtered off, washed with ethanol (ml). The obtained protected tetrapeptide (R g, 0.80) is dissolved in 25 ml of 8N. HCl in dioxane, after 15 minutes, 70 ml of anhydrous ether is added to the solution, the precipitated precipitate is filtered off, washed twice with ether and dissolved in 30 ml of DMF. Triethylamine was added to the solution to a pH of 8.0 and then 2.4 g of Glp-OPfp. The reaction mixture is stirred for 1 h, 100 ml of ethanoi are added, the precipitated product is filtered off and rinsed with ethanol (2 "20 ml). 3.9 g of Z-Glp-Arg (NOr,) -Lys (Z) -Asp (OBzl) -Val-ONB with m.p. 166172C, R 0.80. 2.2 g of Z-Glp-Arg (NO) -Lys (Z) -Asp) -Val-ONB are suspended in 50 ml of 51 90% -HCl Acetic KVicjioTbi, 1 g of 5% Pd / C is added and 4 h hydrated. Then the catalyst is filtered off, washed with 10 ml of 90% acetic acid, the combined filtrate is evaporated, the residue is triturated with 30 M of ethanol, the precipitate formed is filtered off, sifted with ethanol (2 X 10 ml) and dried. . As a result, 1.12 g (, 93%) V is obtained. The resulting product is purified with a column chromatography on silica gel SI-100 using the following system as an eluant: methanol / water 1: 1. As a result, 0.74 g of V -51.3 ° (with 0.9; 10% acetic acid) is obtained. Similarly, a number of other peptides are obtained, the physicochemical characteristics of which are listed in Table. 1-2. Immunomodulatory activity of the described compounds was studied in vitro and in vivo using known methods. I. in vitro. The study on active E-sockets was carried out using the modified method of Wybran et al. With lymphocytes of partially healthy, partly austoimmuno-sick people (rheumatoid arthritis and systemic lupus erythematosus). To 50 ml of cell suspension of lymphocytes, review by circumstances, add 100 ml of the test substance diluted to a concentration of from 10 to 10 mol / l. The mixture was incubated at 37 ° C in air. Containing 5% CO j for 60 min and then mixed with 50 ml of 1% suspension of erythrocytes (sheep). Then, for 10 minutes, the centrifugals were rotated with a speed of 1000 minutes. After this, the glass pieces were put on a modified shaking machine to combat cholelithiasis and shaken for 30 seconds {shaking frequency: 65 minutes, lifting height 8 cm). In order to fix the sockets to each tube, 50 ml of 0.1% glutaraldehyde was added. After 3 minutes under the microscope, there were more than three lymphocytes, which bound erythrocytes derived from sheep, and the total number of cells was evaluated. Separated lymphomas; ites contained macrophages and polymorphono-nuclear cells (max., But 10%) as a contamination. Often, puvieTKH binding cells were corrected in each case to this value. The results are presented in Table. 3-4. Inhibition test with azathioprine {- sockets. Cell suspension containing 2 to 10 lymphocytons / ml is obtained from the blood of healthy donors, chosen randomly. A test for inhibition of azathioprine E-rosettes is performed by corjiacbio to the previously described method. Briefly, this method consists of administering 500 μl of azathioprine and 200 μl of HBSS without additives, or containing the test substance, into 200 μl of the cell suspension. The substances are tested at concentrations ranging from 1 ° C to 10 mol / L. As a comparative experiment, 200 μl of the cell suspension and 400 μl of HBSS are mixed. The resulting mixtures are incubated in air containing 5% carbon dioxide at 37 ° C for 1 h, then mixed with 200 μl of a suspension of 1% SRBC and centrifuge 11) at a temperature of 90 g for 5 min. 400 µl of the overhead fraction (liquid) is removed and, after careful resuspension, at least 400 cells are taken to calculate the E outlets (formation of the outlet — when 3 or more SRBCs surround one lymphocyte). Statistical analysis is performed using Student's t distribution. Due to the different activity in relation to the formation of E-rosettes in lymphocytes obtained from different donors and their different inhibition by azatnoprin, substances are characterized by their ability to restore the activity of lymphocytes to the formation of E-rosettes, which is inhibited by azatochnome expressed in% recovery (R%):. O i5Kc; 2l MClA-ERFC) ERFC - Az-ERFC where ERFC and Az-ERFC denote the average percentage of cells that form E-sockets, without an inhibitor and in the presence of azathioprine, respectively. Exp-ERFC is a pro-UEFJT of cells forming E-rosettes in the presence of azathioprine and experimentally Io substance. The resulting re: ultata 111 are presented in Table. 5. II. in vivo. one . In order to study the effect on antibody production, the Tsetlowski method was chosen. Winter to rats at the latest at the 12th hour after their birth was intraperitoneally injected with the substance to be studied in the form of 25 ml of liquid with a concentration from 4-1U to 410 mol / l (a single dose for every 9 animals). At the age of 14 days, the animals were immunized by intraperitoneal administration to each 0.5 ml of 5% sheep erythrocyte suspension, and on the 7th day after immunization, the animals were bled by decapitation. The blood of every three animals is pooled, centrifuged for 3 minutes at a speed of 3000 minutes, and the antibody titer is determined by the method Tak tsy in the thus obtained short. The results were expressed as an agglutination titer, with the highest serum dilution at which agglutination was again seen as the titer. The results are summarized in table. 6
    [2]
    2. The number of cells producing spe- cific antimatter was determined using the Ganningham method. The essence of the method is that a homogeneous suspension is prepared from the cells of the spleen of immunized animals, a suspension of sheep erythrocytes and complement is prepared and introduced into the chamber suitable for the development of single-cell layers. Around the cells producing antimatter, a gradual halo is formed and the number of these halos ) is identical with the number of cells, irchitnod sneeze. ci; digital antimatter (Plagito forming cells, PFC). Experimental animals after a maximum of 12 hours after their rodepi were treated with the substance to be studied once every time. Using the () method, each substance was studied in three doses. On the 7th day after immunization, the ability of the spleen cells steamed from animals to form Plague was studied. In tab. 7 indicates the quotient of the number of Plagues of treated animals and the number of Plagues of untreated control animals. I As can be seen from the data given in table. 3-7, the compounds obtained by the proposed method have a broad spectrum of immunomodulatory effects in combination with low toxicity. The invention of the method of producing peptides of the general formula X-Arg-Lys-V where X is hydrogen, Glp; V-Asp, Asp-Val, Asp-Val-NH, Asp-Val-OMe, Asn-Val, Asp-Ala, Asp-lie, Ala-Val, Glu-Val, Asu-Val, in the form of acid addition salts, o tl and the fact that the synthesis is carried out by stepwise growth of the peptide chain, starting from C-terminal amino acid ester, by the method of activated esters and by the method of shifted anhydrides, followed by cleavage of the protective groups from the final protected peptide by catalytic hydrogenolysis. Properties of free peptides
     with 1, in 10% acetic acid.
     chromatographed in a column filled with silica gel S1-100, water and methanol 1: 1. AcOH acetic acid.
    I link a E-rosette activity of lymphocytes suffering from renthondma arthritis (expressed as a percentage of lymphocyte activity, p-4)
    blitz 3
    Binding E-roetix activity of lushfocytes healthy activity of lymphocytes, n "4
    T.avlitsa 4 percent
    15 16Arg-Lya-Aap-lU 33.2 30.7 15.0 17Clp-Atg-Lys-Asp-Val-Tyr 24.1 29.9 25.5
    P 0.05 g F test (with one parameter-variable assay, based on TP5); P 0.01 F test (with one parameter-variable assay, based on TP5); R 0.05 Student anachntel action.
    The effect of analogs, TP-S n levanieol on azathioprine inhibited by the formation of E-networks
    EPFC
    AZ-ERFC
    Compound
    45.9 ± 3.0I4.8i5.541.0t8, l yr
    56,, 2I6,2 ± l, 829.4t5,6 l
    , 47,4t4,312,, 934,016,7
    53.616.316.8 + 4.739.2t6.0 Hj 64.6 ± 3.724, 813.3tl, 3 Me
    4. 54.4i4.713,, 016.7t4.7 al
    52.414.411,713,317, 4 71.8 + 1.823,, 519,, 2
    .- S4,6t |, 619,, 921,, 0
    46, Oil, 311.211.022.4i6.0
    57, 721.6 + 7.531.6i4.3
    56, 313.7 + 2.421,713.0
     54,, 619,111,99,, 1
    58,716,619, 6-18,715,2
    56,, 313,, 421,915,8 "l-Tyr
    64,415,022,9i3,924,611.4
    In vivo effect, complete antibody production, expressed as agglutination titer (At SD antibody titer) 12,0108, 3 3Arg-Lys-Asp-Val-Tyr I0,5t |, 5 2Arg-Lys-Asp-Ala 6, 3Arg -Lys-asp
    sixteen
    1277903
    Continuation of table 4
    -2.5; +2.3 5.8
    Table 5
    Recovery in O, in the presence of compound in a concentration of mol / l
    ..:
    47 ,,, 2} 3,, 8l4.0 26,744,6
    30 ,,., 4 29,, 0 31,, 3
    32,5t6, l46,417.0 35, 6 35,, 5
    33 ,,,,, 949 ,,, 5
    17.413.615,, 6 23,, 8 14,, 1
    I7.9t3.818.316.0 28.8i5.7 11,, 8
    23.3 + 6.0 Ib, 9i5.3 28.516.1 12.213.5
    37 ,,,, 5 18,, 2 42,417.3
    15.612.027.914.4 26.216.8 37.116.6
    ia ,, 223,514.1 22,, 8 30,, 6
    26,8t5,540, 9 38,415,8 27,, 0
    13, 330,014.9 25.8110.4 22, 2
    17.412.422,, 1 2l, ll8.3 11.813.0
    30, 117,, 6 22,315.8 28.817.2
    I8.4i8.615,813.6 10, 8 12.814.0
    29, 327, 4 40,117.8 12.816.0
    Table 6 34.932.035.5 29.422.529.9 10.712.3 9.0.1.7 --9.311.5 11.510.9 -12.010-9.9il, 5-7, 6. -6,011,2 5,211,3
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1277903A3|1986-12-15|Method of producing peptides as acid-additive salts
    US5663297A|1997-09-02|Antithrombic peptides
    IE50244B1|1986-03-05|Peptides and process for their manufacture
    US4504415A|1985-03-12|Synthesis of thymosin α1 and desacetyl thymosin α1
    US3705140A|1972-12-05|Peptides related to the c-terminal sequence of cck-pz and caerulein
    EP0659193B1|1997-12-10|Platelet aggregation inhibitors
    US4517119A|1985-05-14|Synthesis of thymosin α1
    KISFALUDY et al.1983|Immuno-regulating peptides, I. Synthesis and structure-activity relationships of thymopentin analogs
    US5093320A|1992-03-03|Novel peptides inhibiting the maturation of t-lymphocytes and the activity of macrophages, pharmaceutical compositions containing them and process for preparing same
    EP0723552B1|2002-10-23|Oligopeptides derived from c-reactive protein fragments
    Rodriguez et al.1985|Peptide sweeteners. 8. Synthesis and structure-taste relationship studies of L-aspartyl-D-alanyl tripeptides
    US4290943A|1981-09-22|Method of preparing polypeptides
    Mokotoff et al.1990|Thymosin-like peptides as potential immunostimulants. Synthesis via the polymeric-reagent method
    US3915948A|1975-10-28|Sarcosyl-L-arginyl-L-valyl-L-tyrosyl-L-valyl-L-histidyl-L-proline
    DE2324239C3|1975-05-28|Process for the preparation of biologically active polypeptides containing asparaginyl groups
    DE2804566A1|1979-05-17|POLYPEPTIDES, THE METHOD OF MANUFACTURING THEM AND MEDICINAL PRODUCTS CONTAINING THEY
    US4058512A|1977-11-15|Synthetic peptides having growth promoting activity
    Schattenkerk et al.1973|Studies on polypeptides xiv synthesis of possible rennin substrates
    AT402822B|1997-09-25|SDK PEPTIDE, METHOD FOR THE PRODUCTION THEREOF AND THERAPEUTIC COMPOSITIONS CONTAINING IT
    US3790555A|1974-02-05|Octapeptide derivative of gonadotropinreleasing hormone
    US4491579A|1985-01-01|Peptides
    US4962225A|1990-10-09|Aspartic acid derivatives
    De Leer et al.1973|Synthesis of human growth hormone sequences. Solid‐phase synthesis of protected 1‐10 and 6‐10 HGH
    RU2144038C1|2000-01-10|Peptide used for inhibition of pepsin release, pharmaceutical composition
    JPH0645637B2|1994-06-15|Tripeptide with immunostimulatory activity
    同族专利:
    公开号 | 公开日
    US4428938A|1984-01-31|
    DK264782A|1982-12-13|
    DK157764B|1990-02-12|
    EP0067425B1|1985-09-18|
    CA1241643A|1988-09-06|
    HU185263B|1984-12-28|
    JPS5849350A|1983-03-23|
    AT382625B|1987-03-25|
    BG60738B2|1996-01-31|
    JPH0357920B2|1991-09-03|
    DK157764C|1990-07-09|
    EP0067425A1|1982-12-22|
    AU551770B2|1986-05-08|
    IL66034A|1985-09-29|
    ATA227082A|1986-08-15|
    DE3266354D1|1985-10-24|
    IL66034D0|1982-09-30|
    AU8479982A|1982-12-16|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO1989006134A1|1987-12-30|1989-07-13|Vsesojuzny Kardiologichesky Nauchny Tsentr Akademi|Pharmaceutical preparation for treating immunodeficiency conditions|
    WO1996026955A1|1995-03-02|1996-09-06|Vladislav Isakovich Deigin|Peptide and a method of obtaining it|
    US6159940A|1996-02-28|2000-12-12|Immunotech Developments Inc.|Method for modulating hemopoiesis|US4190646A|1975-11-11|1980-02-26|Sloan-Kettering Institute For Cancer Research|Polypeptide compositions and methods|
    GB1565032A|1978-01-27|1980-04-16|Sloan Kettering Inst Cancer|Polypeptide compositions and methods for their manufacture|
    CA1157466A|1979-04-12|1983-11-22|Gideon Goldstein|Peptides having thymopoietin-like activity|
    DE2938420A1|1979-09-22|1981-04-09|Hoechst Ag, 6000 Frankfurt|NEW PEPTIDES AND METHOD FOR THEIR PRODUCTION|
    US4261886A|1980-03-13|1981-04-14|Ortho Pharmaceutical Corporation|Peptides having thymopoietin-like activity|IT1164225B|1983-05-13|1987-04-08|Anic Spa|INVERTED ANALOGS OF PENTAPEPTIDE ENHANCING BRADICHINA BPP5A AND METHODS FOR THEIR PREPARATION|
    US4686282A|1983-08-12|1987-08-11|Immunetech, Inc.|Immunotherapeutic polypeptide agents which block immune complex binding to immunoglobulin Fc receptors|
    US4579840A|1983-08-12|1986-04-01|Immunetech Pharmaceuticals|Method of blocking immune complex binding to immunoglobulin Fc receptors|
    DE3421614A1|1984-06-09|1985-12-12|Hoechst Ag, 6230 Frankfurt|METHOD FOR PRODUCING PENTAPEPTIDES WITH EFFECT ON THE IMMUNE SYSTEM AND INTERMEDIATE PRODUCTS OF THIS METHOD|
    US4585757A|1984-07-27|1986-04-29|Texas Tech University Health Sciences Center|Hypotensive active peptides|
    JPH0533718B2|1984-12-22|1993-05-20|Ajinomoto Kk|
    JPH055585B2|1985-07-18|1993-01-22|Toyota Motor Co Ltd|
    FR2591227B1|1985-12-06|1988-11-10|Pasteur Institut|PEPTIDES CAPABLE OF INHIBITING INTERACTIONS BETWEEN LAV VIRUSES AND T4 LYMPHOCYTES, DERIVATIVES THEREOF AND THEIR APPLICATIONS|
    IT1188645B|1986-04-09|1988-01-20|Ellem Ind Farmaceutica|TRIPEPTIDE WITH IMMUNOSTIMULANT ACTIVITY|
    HUT46044A|1986-11-21|1988-09-28|Richter Gedeon Vegyeszet|Process for producing immunstimulant peptides inhibiting multiplication of leukaemic cells and pharmaceutics comprising same|
    HU199878B|1987-06-19|1990-03-28|Berlin Chemie Veb|Process for producing acylated splenopentynes and pharmaceutical compositions comprising such compounds as active ingredient|
    US4904802A|1987-06-30|1990-02-27|Ajinomoto Co., Inc.|Imides|
    IT1222437B|1987-08-04|1990-09-05|Ellem Ind Farmaceutica|TRIPEPTIDES USEFUL AS IMMUNOSTIMULANTS AND IN THE PREVENTION OF METASTASES AND RELATED PREPARATION PROCEDURE|
    FR2622587B1|1987-10-30|1990-12-21|Inst Vaisseaux Sang|PEPTIDE LYSYL-ARGINYL-ASPARTYL-SERINE AND ITS APPLICATIONS AS A MEDICAMENT, ESPECIALLY ANTITHROMBOTIC|
    US5814611A|1988-12-14|1998-09-29|Cytoven J.V.|Pharmaceutical for the therapy of immune deficiency conditions|
    US5807830A|1987-12-30|1998-09-15|Cytoven J.V.|Method for treatment of purulent inflammatory diseases|
    US5811399A|1988-12-14|1998-09-22|Cytran, Inc.|Pharmaceutical dipeptide compositions and methods of use thereof: immunodepressants|
    US5770576A|1989-08-30|1998-06-23|Cytran, Inc.|Pharmaceutical dipeptide compositions and methods of use thereof: systemic toxicity|
    US5728680A|1987-12-30|1998-03-17|Cytoven J.V.|Methods for normalizing numbers of lymphocytes|
    US6136788A|1987-12-30|2000-10-24|Cytran, Inc.|Pharmaceutical preparation for the therapy of immune deficiency conditions|
    DK15888D0|1988-01-14|1988-01-14|Carlsberg Biotechnology Ltd|ENZYMATIC PROCEDURE FOR PREPARING IMMUNO MODULATING PENTAPEPTIDES AND INTERMEDIATES FOR USING THE PROCEDURE|
    NZ229004A|1988-05-19|1993-09-27|Immunobiology Res Inst Inc|Tetrapeptides having t cell helper acitivity|
    HU201095B|1988-06-14|1990-09-28|Richter Gedeon Vegyeszet|New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions|
    DE68926269T2|1988-06-30|1996-08-14|Astra Ab|Dermorphin analogs, their manufacturing process, pharmaceutical compositions and method of therapeutic treatment using the analogs|
    US5602100A|1988-06-30|1997-02-11|Astra Ab|Dermorphin analogs having pharmacological activity|
    US5225400A|1988-07-29|1993-07-06|Ellem Industria Farmaceutica S.R.L.|Immunostimulating peptides, a process for their preparation and pharmaceutical compositions containing them|
    US5316775A|1988-08-04|1994-05-31|Kremers-Urban Company|Method of treating hepatitis B infection|
    US5284664A|1988-08-04|1994-02-08|Kremers-Urban Company|Method of treating the symptoms of Alzheimer's disease|
    US5334395A|1988-08-04|1994-08-02|Kremers-Urban Company|Method of treating an epstein-barr viral infection|
    US5055296A|1988-08-04|1991-10-08|Wagle Sudhakar S|Method of treating chronic fatigue syndrome|
    US5013546A|1988-08-23|1991-05-07|Imreg, Inc.|Methods for modulating antibody production in treating patients with AIDS, ARC and other diseases|
    WO1990003180A1|1988-09-30|1990-04-05|Immunobiology Research Institute, Inc.|Peptides having t cell suppressor activity|
    US5036050A|1989-01-12|1991-07-30|Immunobiology Research Institute, Inc.|Compositions containing thymopentin for topical treatment of skin disorders|
    HU201964B|1989-01-13|1991-01-28|Richter Gedeon Vegyeszet|Process for producing peptides inhibiting maturation of t-lymphocytes and activity of macrophages, as well as pharmaceutical compositions comprising same|
    DD296084A5|1989-07-27|1991-11-21|Adw|PROCESS FOR THE MANUFACTURE OF HUMAN SPLENINE DERIVATIVES|
    IT1237474B|1989-10-05|1993-06-07|Polifarma Spa|TRIPEPTIDIC COMPOUNDS AND THEIR PHARMACEUTICAL USE AS IMMUNO-MODULATORS|
    HU205952B|1990-08-23|1992-07-28|Richter Gedeon Vegyeszet|Process for producing cristalline h-arg-lys-asp-oh and h-arg-lys-asp-val-oh and pharmaceutically active compositions containing them|
    IT1244548B|1991-02-06|1994-07-15|Poli Ind Chimica Spa|5-OXO-L-PROLIN DERIVATIVES AND THEIR PHARMACEUTICAL APPLICATIONS|
    US6100380A|1991-10-28|2000-08-08|Cytran, Inc.|Immunomodulating peptides and methods of use|
    US6066622A|1991-10-28|2000-05-23|Cytran, Inc.|Immunomodulating peptides and methods of use|
    US5585359A|1994-09-29|1996-12-17|Merck & Co., Inc.|Inhibitors of farnesyl-protein transferase|
    JP2001500029A|1996-08-12|2001-01-09|エムゲーベーエンドスコピッシェゲレーテゲゼルシャフトミットベシュレンクテルハフツングベルリン|Rigidendoscope with irradiation system|
    US7199102B2|2000-08-24|2007-04-03|The Regents Of The University Of California|Orally administered peptides synergize statin activity|
    US8568766B2|2000-08-24|2013-10-29|Gattadahalli M. Anantharamaiah|Peptides and peptide mimetics to treat pathologies associated with eye disease|
    US20080293639A1|2005-04-29|2008-11-27|The Regents Of The University Of California|Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response|
    US7723303B2|2000-08-24|2010-05-25|The Regents Of The University Of California|Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response|
    FI20012082A0|2001-10-26|2001-10-26|Paeivi Liesi|Biologically active peptides for the correction of nerve damage|
    US6770763B2|2002-06-11|2004-08-03|Bristol-Myers Squibb Company|Asymmetric synthesis of amino-pyrrolidinones|
    US20060205669A1|2004-09-16|2006-09-14|The Regents Of The University Of California|G-type peptides and other agents to ameliorate atherosclerosis and other pathologies|
    RU2414236C2|2004-12-06|2011-03-20|Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье|Method for structural and/or functional improvement of arterioles|
    AU2006242651B2|2005-04-29|2013-05-16|The Regents Of The University Of California|Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response|
    RU2301074C1|2006-05-30|2007-06-20|Общество С Ограниченной Ответственностью "Сиа Пептайдс"|Peptide possessing immunogeroprotective effect, pharmaceutical composition based on thereof and method for its using|
    JP2010537638A|2007-08-28|2010-12-09|ユーエービーリサーチファウンデーション|Synthetic apolipoprotein E mimetic polypeptides and methods of use|
    AU2008296478B9|2007-08-28|2015-03-19|The Uab Research Foundation|Synthetic apolipoprotein E mimicking polypeptides and methods of use|
    US10653747B2|2014-07-31|2020-05-19|Uab Research Foundation|ApoE mimetic peptides and higher potency to clear plasma cholesterol|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    HU811755A|HU185263B|1981-06-12|1981-06-12|Process for producing peptides effective on the immuncontroll analogous with the tp5|LV930047A| LV5275A3|1981-06-12|1993-01-18|Peptide acquisition is a sort of addictive clutches|
    [返回顶部]